Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Comparing Side Effects of Cinnovex With Avonex in Relapsing Remitting Multiple Sclerosis Patients



Etemadifar M1 ; Maghzi AH2 ; Hoseinzadeh A3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. Department of Neurology, School of Medicine, Najaf Abad Azad University, Isfahan, Iran

Source: Journal of Isfahan Medical School Published:2009

Abstract

Background: Multiple Sclerosis (MS) is a demyelinating disease of central nervous system with an unknown etiology. Beta-Interferon is now widely used for treatment of MS which is believed to slow down the disease progression. This study was designed to compare the side-effects of Avonex and the Iranian 1-a Beta-Interferon, Cinnovex, which are biosimilars. Methods: This was a clinical trial study in which fifty one MS patients were recruited from the neurology departments of Al-Zahra and Shariati hospitals in 2007. Twenty one patients were receiving Avonex and thirty patients were receiving Cinnovex. These patients were followed for 3 months to compare the side-effects of the drugs between two groups. Findings: The most prevalent side effect observed was influenza like symptoms in all patients receiving Avonex and in 83.3% of patients receiving Cinnovex. There were no cases of seizure or diarrhea in any of groups. In this study, there were no significant differences between two groups in respect to experienced side-effects. Conclusion: This study with a short duration follow-up of 3 months demonstrated no significant differences between the two groups in case of experienced side-effects. © 2009, Isfahan University of Medical Sciences(IUMS). All rights reserved.
Related Docs
View other Related Docs
1. A Report of Multiple Sclerosis Patients Treated by Cinnovex™ in Iran, Tehran University Medical Journal (2010)
2. Multiple Sclerosis in Isfahan, Iran, International Review of Neurobiology (2007)
3. Antibodies to Interferon Beta in Patients With Multiple Sclerosis Receiving Cinnovex, Rebif, and Betaferon, Journal of Korean Medical Science (2013)
4. Effect of Different Treatments on Retinal Thickness Changes in Patients With Multiple Sclerosis: A Review, CNS Neuroscience and Therapeutics (2025)
5. Comparison Effect of Prescription Drugs on the Occurrence and the Number of Attacks in Patients With Multiple Sclerosis, Journal of Isfahan Medical School (2018)
6. Neutralizing Antibodies in Multiple Sclerosis Patients on Weekly Intramuscular Avonex and Biosimilar Interferon Beta-1A (Cinnovex): Comparing Results of Measurements in Two Different Laboratories, Journal of Immunological Methods (2013)
7. Interferon-Beta in Pediatric Multiple Sclerosis Patients: Safety in Short-Term Prescription, Acta Medica Iranica (2012)
8. Comparison of the Efficacy and Side Effects of Ifn Beta 1-A (Rebif) and a Biosimilar Product (Recigen) in Patients With Multiple Sclerosis, Journal of Isfahan Medical School (2012)
Experts (# of related papers)
View all Related Experts
Vahid Shaygannejad (50)
Masoud Etemadifar (39)
Other Related Docs
9. Designing of an Elisa Method for the Measurement of Serum Antibodies Against Interferon-Beta and the Study of the Frequency of These Antibodies in Patients With Multiple Sclerosis Treated With Cinnovex, Journal of Isfahan Medical School (2012)
10. Epidemiology of Multiple Sclerosis in Iran: A Systematic Review, European Neurology (2013)
11. Prevalence of Multiple Sclerosis (Ms) in Iran: A Systematic Review and Meta-Analysis, Neurological Sciences (2022)
12. Effects of Rivastigmine on Memory and Cognition in Multiple Sclerosis, Canadian Journal of Neurological Sciences (2008)
13. Prevalence of Multiple Sclerosis in Isfahan, Iran, Neuroepidemiology (2006)
14. Rituximab and Glatiramer Acetate in Secondary Progressive Multiple Sclerosis: A Randomized Clinical Trial, Acta Neurologica Scandinavica (2021)
15. Rapid Exacerbation of Multiple Sclerosis Following the Initiation of Interferon-Β: Report of Nine Cases, Journal of Research in Medical Sciences (2011)
16. Comparison of Betaferon, Avonex, and Rebif in Treatment of Relapsing-Remitting Multiple Sclerosis, Acta Neurologica Scandinavica (2006)
17. Efficacy and Safety of Peginterferon Beta-1A Compared to Interferon Beta-1A in Relapsing Remitting Multiple Sclerosis Patients: A Phase 3, Randomized, Non-Inferiority Clinical Trial (Pegintegrity), Multiple Sclerosis and Related Disorders (2024)
18. An Interdependence Between Gapvd1 Gene Polymorphism, Expression Level and Response to Interferon Beta in Patients With Multiple Sclerosis, Journal of Neuroimmunology (2021)
19. Safety and Effectiveness of Cinnomer® on Disease Characteristics, Depression, and Quality of Life of Patients With Multiple Sclerosis: A Phase Iv, Post-Marketing, Prospective, Multicenter Study, Archives of Iranian Medicine (2023)
20. Interdependency of Ninj2 Gene Expression and Polymorphism With Susceptibility and Response to Interferon Beta in Patients With Multiple Sclerosis, International Journal of Neuroscience (2024)
21. Comparison of Interferon Beta Products and Azathioprine in the Treatment of Relapsing-Remitting Multiple Sclerosis, Journal of Neurology (2007)
22. Investigating the Occurrence of Femoral Head Avascular Necrosis in Patient With Multiple Sclerosis Treated With Interferon-Beta, Journal of Isfahan Medical School (2018)
23. Comparison of the Expression of Mir-326 Between Interferon Beta Responders and Non-Responders in Relapsing-Remitting Multiple Sclerosis, Cell Journal (2020)
24. Outcome of Covid-19 Infection in Multiple Sclerosis Patients Receiving Disease-Modifying Therapies, Journal of Research in Medical Sciences (2021)
25. Immunoregulatory Effects of Silymarin on Proliferation and Activation of Th1 Cells Isolated From Newly Diagnosed and Ifn-ß 1B -Treated Ms Patients, Inflammation (2019)
26. Prognostic Value of Intrathecal Igg Synthesis in Multiple Sclerosis: A Study in 54 Patients, Tehran University Medical Journal (2008)
27. Concurrent Glioma and Multiple Sclerosis: A Systematic Review of Case Reports, Multiple Sclerosis and Related Disorders (2024)
28. Prescription Trends of Disease-Modifying Treatments for Multiple Sclerosis in Iran Over the Past 30 Years, Multiple Sclerosis and Related Disorders (2022)
29. Comparison of the Effect of Aspirin and Amantadine for the Treatment of Fatigue in Multiple Sclerosis: A Randomized, Blinded, Crossover Study, Neurological Research (2012)
30. Anti-Cd20 Therapies for Pediatric-Onset Multiple Sclerosis: A Systematic Review, Multiple Sclerosis and Related Disorders (2024)
31. Th1, Th2 and Th17 Cytokine Profile in Patients With Multiple Sclerosis Following Treatment With Rapamycin, Iranian Journal of Immunology (2016)
32. Prevalence of Familial Multiple Sclerosis in Isfahan, Iran, Journal of Isfahan Medical School (2011)
33. The Effectiveness of Natalizumab Vs Fingolimod–A Comparison of International Registry Studies, Multiple Sclerosis and Related Disorders (2021)
34. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis, JAMA - Journal of the American Medical Association (2019)
35. Prevalence of Cognitive Impairment (Ci) in Patients With Multiple Sclerosis (Ms): A Systematic Review and Meta-Analysis, Caspian Journal of Internal Medicine (2024)
36. Risk Factors of Severe Covid-19 in People With Multiple Sclerosis : A Systematic Review and Meta-Analysis, Revue Neurologique (2022)
37. Safety of Sinopharm Vaccine for People With Multiple Sclerosis: Study of Adverse Reactions and Disease Activity, Multiple Sclerosis and Related Disorders (2022)
38. Side Effects of Methylprednisolone Pulse Therapy in Treatment of Multiple Sclerosis, Journal of Isfahan Medical School (2012)
39. Effectiveness of Multiple Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis: Causal Inference to Emulate a Multiarm Randomised Trial, Journal of Neurology, Neurosurgery and Psychiatry (2023)
40. Using Discrete Choice Experiment to Determine Willingness to Pay for Interferon-Beta Drugs by Multiple Sclerosis Patients, Iranian Journal of Pharmaceutical Sciences (2018)
41. Higher Latitude Is Significantly Associated With an Earlier Age of Disease Onset in Multiple Sclerosis, Journal of Neurology, Neurosurgery and Psychiatry (2016)
42. Pure Spinal Multiple Sclerosis: A Case Series of a Possible New Entity, Journal of Neuroimmunology (2025)
43. Cytokine Gene Expression in Newly Diagnosed Multiple Sclerosis Patients, Iranian Journal of Allergy, Asthma and Immunology (2015)
44. Cytomegalovirus Seroposivity in Iranian Multiple Sclerosis: A Randomized Case-Control Study, Pakistan Journal of Medical Sciences (2012)
45. Multiple Sclerosis Relapse After Covid-19 Vaccination: A Case Report-Based Systematic Review, Journal of Clinical Neuroscience (2022)
46. Predictors of Catching Covid-19 Infection During Pandemic Stage in Patients With Multiple Sclerosis (Ms), International Journal of Preventive Medicine (2022)
47. Chlamydia Pneumoniae Seropositivity in Iranian Patients With Multiple Sclerosis: A Pilot Study; [Obecnosc Przeciwcial Przeciw Chlamydia Pneumoniae Wsrod Iranskich Chorych Na Stwardnienie Rozsiane: Badanie Pilotazowe], Neurologia i Neurochirurgia Polska (2011)
48. Comparative Effectiveness of Natalizumab, Fingolimod, and Injectable Therapies in Pediatric-Onset Multiple Sclerosis: A Registry-Based Study, Neurology (2024)
49. Stress Differentially Predicts Multiple Sclerosis Relapses, Neurology Asia (2014)
50. Evaluating the Effect of Adding Fish Oil to Fingolimod on Tnf-Α Il1β Il6, and Ifn-Γ in Patients With Relapsing-Remitting Multiple Sclerosis: A Double-Blind Randomized Placebo-Controlled Trial, Clinical Neurology and Neurosurgery (2017)